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Abstract
Background: Aberrant mitochondrial function, including excessive reactive oxygen species (ROS) production, has
been implicated in the pathogenesis of human diseases. The use of mitochondrial inhibitors to ascertain the sites in
the electron transport chain (ETC) resulting in altered ROS production can be an important tool. However, the response
of mouse mitochondria to ETC inhibitors has not been thoroughly assessed. Here we set out to characterize the
differences in phenotypic response to ETC inhibitors between the more energetically demanding brain mitochondria
and less energetically demanding liver mitochondria in commonly utilized C57BL/6J mice.
Results: We show that in contrast to brain mitochondria, inhibiting distally within complex I or within complex III does
not increase liver mitochondrial ROS production supported by complex I substrates, and liver mitochondrial ROS
production supported by complex II substrates occurred primarily independent of membrane potential. Complex I, II, and
III enzymatic activities and membrane potential were equivalent between liver and brain and responded to ETC. inhibitors
similarly. Brain mitochondria exhibited an approximately two-fold increase in complex I and II supported respiration
compared with liver mitochondria while exhibiting similar responses to inhibitors. Elevated NADH transport and
heightened complex II–III coupled activity accounted for increased complex I and II supported respiration, respectively in
brain mitochondria.
Conclusions: We conclude that important mechanistic differences exist between mouse liver and brain mitochondria
and that mouse mitochondria exhibit phenotypic differences compared with mitochondria from other species.
Background
Mitochondrial dysfunction has been implicated in a grow-
ing number of disorders. The etiologies of these syn-
dromes have been associated with an imbalance in
mitochondrial reactive oxygen species (ROS) production,
which consists principally of the generation of superoxide
and hydrogen peroxide. Mitochondrial ROS production
has been well characterized in neurodegenerative condi-
tions, including Alzheimer’s disease [1–3], Parkinson’s dis-
ease [1, 3–5], amyotrophic lateral sclerosis [1, 6], and
Huntington’s disease [1, 2, 7]. The dysfunction of β cells in
both type 2 and type 1 diabetes [8–11], has been linked to
mitochondrial ROS production and increased superoxide
production has been shown to cause DNA damage leading
to poly(ADP-ribose) polymerase activation, subsequently
Glyceraldehyde 3-phosphate dehydrogenase inhibition, as
well as induction of the main pathways of hypergly-
cemia induced pathology [12]. ROS generated by the
mitochondria have also been implicated in the aging
process [13–16] as well as in cardiovascular disorders
such as hypertension [17–19], atherosclerosis [20–25],
and myocardial infarction [26, 27].
Many studies have sought to determine the mecha-
nisms of mitochondrial ROS production. Inhibitors that
act on different sites of the electron transport chain
(ETC) have been extensively used to localize and quan-
tify mitochondrial ROS production. Complex I and III
redox centers have been implicated as the major sites of
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mitochondrial ROS production [28–30], with recent data
suggesting complex II is also capable of producing ROS
[31, 32]. Within complex I, both the flavin mononucleo-
tides (FMN) and a distal site, presumably the ubiquinone
binding site, have been shown to be capable of generating
ROS with the direction of electron flow dictating the rela-
tive contribution from each site [33]. The location of com-
plex III supported ROS production has been shown to be
primarily the cytochrome bc1 complex promoted by a par-
tially oxidized ubiquinone pool [34]. However, the FMN
site within complex I has been shown to be responsible
for the majority of ROS production under ATP gener-
ating conditions [35].
There is reason to believe that mitochondria from
different mouse tissues exhibit unique functional char-
acteristics. Studies using isolated rat mitochondria
have observed variation in the activity of the ETC com-
plexes comparing tissues [36]. The MitoCarta database
has revealed that in mouse tissues many nuclear
encoded mitochondrial proteins have unique tissue
specific expression [37]. Further, it has been shown
that liver mitochondria require less Ca2+ than brain
mitochondria to initiate the mitochondrial permeabil-
ity transition and mouse brain mitochondria were
found to have a more robust ROS increase in response
to complex III inhibitors than rat brain mitochondria
[38]. These differences are not unexpected given the
growing knowledge of the importance of signaling be-
tween the nuclear and mitochondrial genomes. Nuclear
genes are potentially targeted for expression either by
changes in the release of signaling molecules from the
mitochondria (retrograde signaling) or by communica-
tion of nuclear gene products with proteins encoded by
mitochondrial genes (intergenomic interactions) [9, 10,
39]. Indeed, mitochondrial DNA (mtDNA) haplogroups
impact ROS production [9, 10] activating compensatory
mechanisms resulting in the normalization of mito-
chondrial respiration [40]. While mice represent
some of the most widely used models of disease,
there is a lack of information comparing the parame-
ters of mitochondrial function from different mouse
tissues.
We hypothesize that mouse mitochondria will exhibit tis-
sue specific phenotypes. In this report, the effects of
some of the most commonly used ETC. inhibitors-
rotenone, p-chloromercuribenzoate (CMB), diphenyle-
neiodonium (DPI), antimycin A, and myxothiazol-were
tested on various functional parameters of isolated
mouse brain and liver mitochondria. These two tissues
exhibited some similarities in mitochondrial function,
but there were notable differences in respiration and
ROS production. The effect of the panel of inhibitors
demonstrated further divergence between the mito-
chondria isolated from these two tissues.
Results
Method of isolation does not alter function or purity of
liver mitochondria
Historically mitochondria have been isolated from liver
using differential centrifugation [41] and from brain
using a Percoll gradient [42]. To examine if liver mito-
chondria isolated by these two methods would have
measurable differences in functional parameters, we
isolated liver mitochondria using either differential
centrifugation or Percoll and assayed these prepara-
tions for purity and respiration. For these experiments
livers were removed, a lateral bisection was performed,
and each half was subjected to a different procedure of
mitochondria isolation. Liver mitochondria isolated by
the two methods had equal purity as assessed by Western
blot analysis of COX IV protein abundance (Fig. 1a, b), and
did not differ in state two and three respiration (Fig. 1c)
when normalized for protein content. As the mitochondria
resulting from these two isolation methods were equal in
purity and characteristics of mitochondrial function, all
other experimental data in this report were derived using
liver mitochondria isolated by differential centrifugation for
comparison to the historical literature.
Mitochondrial reactive oxygen species production
ROS production was assessed for intact brain and liver
mitochondria in the presence of electron transport chain
inhibitors. In order to determine the optimal inhibitor con-
centration, titration curves were performed for each inhibi-
tor at concentrations of 0, 0.1, 1, 5, 10, and 20 μM in brain
and liver mitochondria utilizing either glutamate and mal-
ate or succinate to support ROS production (Additional file
1: Table S1). ROS production of brain mitochondria utiliz-
ing glutamate and malate was maximal with 5 μM of each
inhibitor and without significant differences among 5, 10,
and 20 μM of each inhibitor (Additional file 1: Table S1).
Addition of inhibitors slightly decreased liver mitochondrial
ROS production utilizing glutamate and malate with max-
imal inhibition reached at 5 μM and without significant dif-
ference among 5, 10, and 20 μM of each inhibitor
(Additional file 1: Table S1). The decrease in brain mito-
chondrial ROS production utilizing succinate was maximal
by 5 μM of each inhibitor without significant difference
among 5, 10, and 20 μM of each inhibitor (Additional file 1:
Table S1). A dose response curve of 0–12.8 μM DMSO
was performed for brain and liver mitochondrial utiliz-
ing either complex I or complex II substrates without
significant differences among the concentrations used
(Additional file 1: Table S2).
Reactive oxygen species production by brain
mitochondria
For brain mitochondria utilizing the complex I sub-
strates glutamate and malate, basal ROS production was
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unchanged by the addition of DPI, while CMB alone re-
sulted in a slight but statistically significant increase
(Fig. 2a). As expected [43], the addition of rotenone in-
creased ROS production from brain mitochondria by
1000 % compared to the basal level. To suppress the
rotenone-induced elevation in ROS production, DPI and
CMB were added in combination with rotenone. Addition
of DPI decreased the rotenone induced increase by
half, whereas the inhibitor CMB resulted in a slight but
non-significant increase in ROS production. The com-
plex III inhibitors antimycin A and myxothiazol in-
creased ROS production by approximately 450 and
650 % from basal level, respectively (Fig. 2a).
Basal ROS production from brain mitochondria respiring
with succinate was characteristically high and 1000 %
higher than ROS during the utilization of complex I sub-
strates (1245 ± 288 pmol H2O2 min
−1 mg−1 [with succinate]
versus 114 ± 17 pmol H2O2 min
−1 mg−1 [with glutamate
and malate]; p < 0.0001). Addition of the Complex I in-
hibitors DPI and CMB each significantly decreased
succinate-mediated ROS production by greater than
90 %, while rotenone significantly lowered ROS pro-
duction by roughly 1-half (Fig. 2c). The presence of the
complex III inhibitors antimcyin A or myxothiazol de-
creased this basal ROS signal to a similar extent as
rotenone (Fig. 2c).
Reactive oxygen species production by liver mitochondria
For liver mitochondria utilizing glutamate and malate as
substrates, neither DPI nor CBM altered basal ROS pro-
duction (Fig. 2b). However, rotenone significantly de-
creased ROS production. The addition of either DPI or
CMB to rotenone-inhibited mitochondria had no further
significant inhibitory effects compared to rotenone alone.
The complex III inhibitors antimycin A and myxothiazol
had no significant effect on ROS production (Fig. 2b).
Liver mitochondria utilizing succinate exhibited a
slight yet significant increase in basal ROS production
compared to liver mitochondria using glutamate and
malate (264 ± 37 pmol H2O2 min
−1 mg−1 [with succin-
ate] versus 181 ± 24 pmol H2O2 min
−1 mg−1 [with glu-
tamate and malate]; p = 0.009). The inhibitors rotenone,
DPI, CMB, and antimycin A each resulted in an approxi-
mately 15–20 % reduction in ROS production. Myxothiazol
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Fig. 1 Purity and function of liver mitochondria comparing isolation with differential centrifugation versus a Percoll gradient. a Western blot. Lanes
1–4 are liver mitochondria isolated by differential centrifugation. Lanes 5–8 are liver mitochondria isolated using a Percoll gradient. Protein was loaded
at 25 μg/lane. COX IV antibody [20E8] (Abcam) was used to detect mitochondrial protein. GAPDH, an enzyme expressed in the cytosol, demonstrates
minimal differences in cytosolic contamination among the preparations. b Densitometry analysis of the immunoblots shows there is no difference in
the amount of COX IV protein in the mitochondrial preparations resulting from these two methodologies. c Respiration. Liver mitochondria were
isolated by either differential centrifugation (open bars) or with Percoll (closed bars) and then tested for respiratory capacity. Mitochondrial respiration
was measured using the complex I substrates glutamate and malate. State 1 respiration was recorded without substrates, subsequently state 2
respiration was recorded after the addition of substrates, and finally ADP (0.5 mM final concentration) was added in order to induce state 3 respiration.
n = 6 for both mitochondrial preparations and for all three respiratory states. Respiratory rates were comparable for the two mitochondria isolated by
the two methods without significant differences
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myxothiazol resulted in a slight but non-significant increase
in ROS production (Fig. 2d).
Comparison of brain and liver mitochondrial ROS
production
Comparing brain and liver mitochondria utilizing glu-
tamate and malate (Fig. 2 a-basal versus b-basal), liver
mitochondria produced more ROS than brain mito-
chondria (p = 0.0002). For both liver and brain mito-
chondria, DPI had no significant effect on ROS
production. CMB resulted in a slight but non-significant
increase in brain ROS production yet had no effect on
liver ROS production. Rotenone drastically increased
ROS production from brain mitochondria yet decreased
liver mitochondrial ROS production. The addition of DPI
to rotenone inhibited the increase in ROS production by
brain mitochondria, and led to a further decrease of liver
mitochondrial ROS. The combination of rotenone and
CMB had no further effect on ROS production from either
brain or liver mitochondria compared with rotenone alone.
Considering complex III inhibitors in the context of
glutamate and malate supported ROS production, anti-
mycin A increased brain ROS, yet this inhibitor did not
affect liver mitochondrial ROS production. Likewise,
Fig. 2 Response of reactive oxygen species production to ETC inhibitors differs between brain and liver mitochondria. Brain (a) and liver (b)
mitochondrial ROS production was assessed utilizing the complex I substrates glutamate and malate. Basal ROS production was recorded for
three minutes. After this time, DPI (10 μM), CMB (10 μM), rotenone (10 μM), rotenone + DPI (10 μM each), rotenone + CMB (10 μM each),
antimycin A (10 μM), or myxothiazol (10 μM) was added to the reaction and ROS production was recorded for an additional two minutes. Brain
(c) and liver (d) mitochondrial ROS production was assessed utilizing the complex II substrate succinate. Basal respiration was recorded for three minutes.
After this time, DPI (10 μM), CMB (10 μM), rotenone (10 μM), antimcyin A (10 μM), myxothiazol (10 μM), or rotenone +myxothiazol (10 μM each; liver only)
was added to the reaction, and ROS production was recorded for an additional two minutes. 150 μg of isolated mitochondria was used for each
experiment. For each comparison, * vs. § < 0.05; * vs. # < 0.001; * vs. †< 0.01; § vs. # < 0.01, § vs. †< 0.01; # vs. †< 0.05. For each condition, n≥ 3
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addition of myxothiazol increased brain ROS production,
but did not alter liver mitochondrial ROS production.
Comparing brain and liver mitochondria utilizing succin-
ate (Fig. 2c, d), brain mitochondria produced significantly
more ROS (p < 0.0001). DPI and CMB each inhibited the
majority of brain mitochondrial ROS production, while
both inhibited liver mitochondrial ROS production to a
lesser extent. Rotenone and antimcyin A both inhibited
ROS production to a slightly greater extent in brain com-
pared with liver mitochondria. However, while myxothiazol
inhibited brain ROS production to a significant extent, this
inhibitor did not significantly block liver ROS production.
Complex I enzymatic activity
Complex I activity was assessed using both input (by fol-
lowing the oxidation of NADH) and output (by following
the reduction of ubiquinone) assays in the presence of
complex I inhibitors. Total complex I activity was compar-
able between brain and liver for both NADH oxidation
(Fig. 3a) and ubiquinone reduction (Fig. 3b). DPI inhibited
NADH oxidation by approximately 30 % and ubiquinone
reduction approximately 50 %, with liver mitochondria be-
ing slightly (yet not significantly) more inhibited. CMB
inhibited complex I activity to a similar extent as DPI,
however brain mitochondria were slightly but significantly
(p = 0.04) more inhibited than liver mitochondria consid-
ering NADH oxidation. Rotenone inhibited the oxidation
of NADH by only 40 % (Fig. 3a), whereas it inhibited the
reduction of ubiquinone by roughly 75 % with no signifi-
cant differences between liver and brain (Fig. 3b).
Complex II and complex III enzymatic activity
Complex II activity in both brain and liver mitochondria
was monitored following the reduction of DCIP. The
specific activity of complex II was obtained by subtract-
ing the malonate insensitive activity from the total activ-
ity. Brain and liver mitochondria showed no significant
difference in specific complex II activity (Fig. 4a).
Complex III activity was measured in the presence of
complex III and complex I inhibitors. Basal activity was
not significantly different comparing liver and brain mito-
chondria. The complex III inhibitor antimycin A inhibited
brain mitochondrial complex III activity by approximately
80 % while liver mitochondria were inhibited by nearly
90 % (p = 0.0038). DPI had only a negligible effect on
complex III activity for both liver and brain mito-
chondria. Conversely, CMB nearly completely ablated
complex III activity for both liver and brain mito-
chondria (Fig. 4b).
Mitochondrial respiration utilizing glutamate and malate
Utilizing glutamate and malate, state 2 and state 3 re-
spiratory rates were more than double for brain
compared with liver mitochondria (Fig. 5a, b). Respira-
tory control ratios (RCR) for isolated brain (4.0 ± 0.3)
and liver (4.3 ± 0.68) mitochondria respiring on glu-
tamate and malate were not statistically different
(p = 0.3). Mitochondrial state 3 respiration was measured
in the presence of Complex I inhibitors (Fig. 5b, c). DPI
inhibited state 3 respiration by around 50 % in brain and
by around 70 % in liver mitochondria. The inhibitory
effect of CMB was slightly more pronounced, inhibiting
brain mitochondria by nearly 75 % and liver mitochondria
by nearly 85 %. Rotenone had a very strong inhibitory
effect, lowering state 3 respiration in both brain and liver
mitochondria by nearly 95 %.
Fig. 3 Complex I enzymatic activity is comparable in mitochondrial
preparations of brain and liver mitochondria. Mitochondrial complex I
enzymatic activity was assessed by following the oxidation of
NADH (a) or the reduction of ubiquinone (b) by 40 μg of isolated
brain or liver mitochondria. Complex I activity was measured over
three minutes. Basal indicates total complex I activity in the
absence of electron transport chain inhibitors. Where indicated,
DPI (10 μM), CMB (10 μM), or rotenone (10 μM) was added before
the initiation of the reaction. Symbols denote comparisons brain
mitochondria treatment groups or liver mitochondria treatment
groups, respectively, as well as comparisons between brain and
liver mitochondria for each treatment. For each comparison, * vs. #
< 0.01; * vs. † < 0.05; # vs. † < 0.05. For each treatment with brain
mitochondria n = 6. For each treatment with liver mitochondria, n = 3
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Mitochondrial respiration utilizing succinate
Brain mitochondrial state 2 and state 3 respiratory rates
were more than double the liver respiratory rates (Fig. 5d).
Again, while the isolated brain mitochondria exhibited an
elevated rate of respiration there were no differences in the
RCR [brain (3.92 ± 0.4), liver (4.1 ± 0.7), p = 0.55] suggesting
that the mitochondria were equally coupled. Mitochondrial
state 3 respiration with succinate was assessed in the pres-
ence of Complex I inhibitors (Fig. 5d, e). DPI inhibited
brain mitochondrial respiration by roughly 60 %, but inhib-
ited liver mitochondria by only 25 %. CMB had a strong ef-
fect, inhibiting brain and liver mitochondrial respiration
96 % and 87 %, respectively. Rotenone had a small effect
on brain mitochondria, inhibiting respiration by 12 %;
yet liver mitochondrial respiration was significantly
inhibited by about 31 %.
Mitochondrial inner membrane potential (Δψm)
Mitochondrial inner membrane potential, Δψm, was
assessed qualitatively in liver and brain mitochondria
utilizing complex I or complex II substrates while in re-
spiratory state 2. There were no significant differences in
basal Δψm between brain and liver mitochondria. With
either complex I or complex II substrates both brain and
liver mitochondria were completely and rapidly depolarized
by the addition of the uncoupler FCCP, and by antimycin
A. Myxothiazol also completely depolarized mitochondria
in each experimental condition yet with slightly slower
Fig. 4 Complex II and III enzymatic activities are similar in mitochondrial preparations of brain and liver mitochondria but differs in response to
Antimycin A. a Mitochondrial complex II enzymatic activity was assessed by following the reduction of DCIP by 1.5 μg of isolated brain or liver
mitochondria over one minute. b Mitochondrial complex III enzymatic activity was assessed by following the reduction of cytochrome c by 20 μg
by isolated brain or liver mitochondria over one minute. Basal indicates the total complex III activity in the absence of electron transport chain
inhibitors. When indicated, antimycin A (10 μM), DPI (10 μM), or CMB (10 μM) was added before the initiation of the reaction. Symbols denote
comparisons among brain mitochondria treatment groups or liver mitochondria treatment groups as well as comparisons between brain and
liver mitochondria for each treatment. For each comparison, * vs. # < 0.01; * vs. † < 0.001; # vs. † < 0.01. For each condition, n = 3
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Fig. 5 Isolated brain mitochondria exhibit a higher respiratory rate and are differentially affected by ETC. inhibitors compared to liver
mitochondria. a Representative trace of brain and liver mitochondrial oxygen consumption using glutamate and malate as a substrate with
or without addition of rotenone where indicated. (b–d) Mitochondrial respiration was supported by glutamate and malate (complex I) (b, c) or
succinate (complex II) (d, e), respectively. State 2 respiration was monitored before the addition of 0.5 mM ADP to induce state 3 respiration. After
achieving maximal state 3 respiration, DPI (10 μM), CMB (10 μM), or rotenone (10 μM) was added. Percent inhibition of respiration achieved by rotenone,
DPI, and CMB was calculated for both glutamate and malate (c) and succinate (e) supported respiration by comparing state 3 respiratory rates to stable
respiratory rates after inhibitor treatments. For each treatment, n≥ 3. P values are indicated comparing brain and liver mitochondria for state 2 and state 3
respiratory rates, as well as state 3 respiratory rates after rotenone, DPI, or CMB treatment. Isolated mitochondria (0.4 mg) were used for each experiment.
For each treatment, brain mitochondria are compared, where a vs. b vs. c< 0.05; liver mitochondria are compared, where x vs. y vs. z< 0.05
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kinetics. Rotenone depolarized brain and liver mitochondria
utilizing glutamate and malate yet with slightly slower kin-
etics than myxothiazol (Fig. 6a, b). As expected, rotenone
did not depolarize brain or liver mitochondria utilizing suc-
cinate (Fig. 6c, d). CMB completely depolarized brain and
liver mitochondria utilizing glutamate and malate or suc-
cinate, yet relatively slowly. DPI resulted in only a slight
depolarization of liver and brain mitochondria utilizing glu-
tamate and malate (Fig. 6a, b) and negligible depolarization
utilizing succinate (Fig. 6c, d).
NADH transport activity is increased in brain
mitochondria
Increased respiration in brain mitochondria linked to
complex I or complex II substrates cannot be attributed
to enzymatic differences as the individual complex I, II,
and III enzymatic activities showed no significant differ-
ences. However, differences in substrate transport could
account for this difference. To determine if differences
in transport of NADH into mitochondria of brain versus
liver the autofluorescence of exogenously added NADH
was followed. The rate of disappearance of NADH autoflu-
orescence was calculated after the addition of ADP. This
rate was corrected for the non-ADP linked rate, which indi-
cated non-ETC. NADH use. NADH transport was in-
creased approximately 3 fold in brain mitochondria
compared with liver mitochondria (p = 0.0012) (Fig. 7a).
Inhibition of the Malate-Aspartate Shuttle Differentially
Regulates Respiration of Liver and Brain Mitochondria
Brain mitochondria have elevated rates of respiration as
well as more rapid transport of NADH when compared to
isolated liver mitochondria. To determine how the height-
ened respiration is controlled by substrate transport we uti-
lized AOA, which inhibits the malate-aspartate shuttle
though selective, competitive inhibition of aspartate amino
transferases. For these studies we combined either brain or
liver mitochondria with glutamate and malate. ADP was
Fig. 6 Mitochondrial membrane potential is not different comparing brain and liver mitochondria and is equally affected by ETC. inhibitors in
both mitochondrial populations. Mitochondrial membrane potential was qualitatively assessed for brain and liver mitochondria in respiratory state
2 utilizing glutamate and malate (a and b, respectively) or succinate (c and d, respectively). Mitochondria (150 μg) were added where indicated
and membrane potential was recorded. At three minutes, 10 μM rotenone (black), 10 μM DPI (red), 10 μM CMB (green), 10 μM myxothiazol
(orange), 10 μg/mL antimcyin A (blue), or 0.4 μM FCCP (gray) were added. Traces are representative of three replicates
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then added in excess to induce sustained maximal res-
piration (state 3). As expected, maximal state 3 respir-
ation of brain mitochondria prior to addition of AOA
was 2149 ± 309 [pmol O2/(s*mL*mg mt protein)]
compared to a rate of 432.5 ± 38 in liver mitochondria
(Fig. 7b). This elevation in respiration mirrors the dif-
ference in substrate transport (Fig. 7a). The final con-
centrations of AOA to achieve full inhibition of state 3
respiration were 7 mM for brain mitochondrial and
6 mM for liver mitochondria. As expected, the respir-
ation rate of brain mitochondria was inhibited with increas-
ing concentrations of AOA. Rates dropped by 41 % at
1 mM, 50 % (2 mM), 56 % (3 mM), 62 % (4 mM), 72 %
(5 mM), 77 % (6 mM), and 91 % (7 mM) with all rates be-
ing statistically different compared to uninhibited state 3
respiration. As previously published [44], liver mitochon-
dria were refractory to respiratory inhibition at lower con-
centrations of AOA. After addition of 1 mM AOA the
O2 consumption by liver mitochondria fell by 20 % but
was not significantly reduced versus liver mitochondria
respiring in the absence of AOA. However, at doses of
2 mM and above respiration of liver was significantly
inhibited dropping by 29 % (2 mM), and then 34 %
(3 mM), 39 % (4 mM), 36 % (5 mM), and 69 % (6 mM).
When comparing the AOA induced changes in respir-
ation rates of brain to liver, the rate of brain mitochon-
drial O2 consumption was significantly different at all
concentrations (Fig. 7b). Further, when comparing the
inhibition of brain mitochondria to uninhibited liver
mitochondria the rate of respiration of mitochondria
isolated from brain was more rapid at doses of AOA
between 1 mM and 4 mM (Fig. 7c). At a dose of 5 mM
AOA the state 3 respiratory rate of brain mitochondria
(607 ± 102) was no longer statistically distinguishable
from AOA-free liver mitochondria. These data provide
evidence that the higher substrate transport by brain
mitochondria drives enhanced respiration and that
through inhibition of the malate-aspartate transporter


























































































































Fig. 7 NADH-linked substrate transport is increased in brain compared with liver mitochondria. a The activity of the malate-aspartate shuttle was
assessed by following the decrease in absorbance of NADH (0.14 mM) at 340 nM. After addition of mitochondria, baseline decrease in absorbance
was recorded. Subsequently, further decrease of absorbance, indicative of malate-aspartate shuttle activity, was recorded after the addition of malate and
glutamate. The data shown represent the average of three independent experiments performed in at least duplicate. b State 3 respiration supported by
the complex I substrates glutamate and malate in the presence of ADP, with the stepwise (1 mM increments) addition of the malate aspartate shuttle in-
hibitor AOA. Traces were compiled from of three independent experiments performed in duplicate. c Brain mitochondrial state 3 respiration was deter-
mined in the presence of increasing concentrations of AOA in comparison with liver mitochondria in state 3 respiration without inhibition by AOA.
Bars are representative of three independent experiments performed in duplicate. In 7b liver and brain mitochondria were compared for an
individual dose of AOA. In 7c brain mitochondria at each AOA dose was compared to untreated liver mitochondria. Notations, ****-p <
0.0001, ***-p < 0.001, **-p < 0.01, N.S-Not significant
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Gene expression of Slc25a10 and Complex II–III coupled
enzymatic activity
Substrate transport was further explored as the etiology for
increased complex II-linked respiration in brain compared
to liver mitochondria. Slc25a10 encodes a dicarboxylate
carrier protein found in the inner mitochondrial membrane
that transports succinate or malate into the mitochondrial
matrix in exchange for HPO4
2− [45]. Slc25a10 expression
was assessed by qRT-PCR. qRT-PCR revealed a significant
increase in Slc25a10 expression in liver compared with
brain tissue (Fig. 8b). Given the lower Slc25a10 expression
in brain tissue, substrate transport via the dicarboxylate car-
rier cannot account for the increased respiratory activity of
brain mitochondria when utilizing complex II substrates.
While complex II and III activities were not significantly
different between brain and liver mitochondria, the shut-
tling of electrons from complex II to complex III is not
assessed by each individual assay and may underlie the dif-
ferences in respiratory rates. By assessing the malonate sen-
sitive reduction of cytochrome c after exogenous addition
of succinate, brain mitochondria exhibited an approxi-
mately 2.5 fold higher complex II–III coupled enzymatic
activity (p =0.0221) (Fig. 8a).
Discussion
Mutations in the mitochondrial genome have been impli-
cated as contributors to human disease and have been
linked with diseases animal models. These illnesses can be
the result of a homoplastic mutation in the mitochondrial
population or as the result of heteroplasmy [46]. In either
case patients do not exhibit a global failure of all tissues
and are generally afflicted with tissue specific pathologies.
Rossignol et al. have shown by determining metabolic con-
trol coefficients, that respiratory flux is regulated at differ-
ent steps when comparing tissues. Due to these results they
posited that these tissue specific regulatory distinctions ac-
count for the tissue sensitivity or specificity of a particular
mitochondrial defect [47]. However, they found that rat
liver and brain mitochondria are both primarily under the
control of ATP synthase and the phosphate carrier [47],
thus not providing an explanation for phenotypic changes
observed herein between brain and liver mitochondria. We
hypothesized that, in addition to metabolic control, the re-
striction of the pathology to specific tissues is likely affected
by tissue specific mitochondrial respiratory function and
ROS production as well as interactions between sequence
variation in the mtDNA and alleles of nuclear encoded
genes. Previously, we have demonstrated that by varying
both the nuclear genome and the mtDNA, changes can be
measured in mitochondrial ROS production [9, 10]. As an
example, a transversion in mt-Nd2 results in decreased
mitochondrial ROS production in mice with tissue specific
phenotypes and also interacts with loci within the nuclear
genome [9, 10].
Determining the sites of ROS production within the
mitochondrial ETC. requires the use of specific respiratory
complex inhibitors that have distinct effects on the produc-
tion of ROS. Interestingly, many widely used ETC. inhibi-
tors have been shown in independent studies to have very
distinct effects on the physiology of mitochondria isolated
from different tissues. Tahara et al. studied the effects of a
variety of ETC. inhibitors on ROS production in brain,
heart, kidney, liver, and muscle tissue from rats [48]. How-
ever, the effects of ETC. inhibitors on mitochondrial func-
tion has not been well characterized in mouse models. In
this paper we set out to characterize the effects of several
ETC. inhibitors on mitochondria isolated from the com-
monly utilized C57BL/6 J mouse strain. We describe the
effects of DPI, CMB, rotenone, myxothiazol, and anti-
mycin A on liver and brain mitochondria by assaying
ROS production, complex I, II, and III activities as well
as mitochondrial oxygen consumption and membrane
potential. Our results identify significant differences
between liver and brain mitochondria, which are dis-
tinct from function of rat mitochondria. Furthermore,
we propose a mechanistic explanation for increased re-
spiratory rates in brain mitochondria.
Brain and liver mitochondria exhibited significant
differences in mitochondrial ROS production (Fig. 2).
Similar to rat brain mitochondria, mouse brain mito-
chondrial ROS production is stimulated by complex I
and III inhibitors while utilizing complex I substrates.
This increased ROS production is largely inhibited by
the DPI corroborating the FMNs as a key site of ROS













































Fig. 8 Complex II–III coupled enzymatic activity is increased in brain
compared with liver mitochondria. a Complex II–III coupled enzymatic
activity was assessed by following the reduction of ferricytochrome c to
ferrocytochrome c at 550 nM by 40 μg of isolated mitochondria. A
baseline was recorded after the addition of ferricytochrome c (15 μM),
alamethacin (30 μg/mL), and rotenone (2 μM). The reaction was initiated
by the addition of freshly isolated mitochondria (200 μg/mL)
preincubated with succinate (20 mM) at 30 °C for 20 min in potassium
phosphate buffer. Malonate (20 mM) was added in parallel wells, and the
specific activity of complex II was obtained by subtracting the malonate
insensitive activity. For brain mitochondria n= 9 and for liver
mitochondria n= 8. b The expression level of Slc25a10 was determined
in brain and liver tissue, respectively, by RT-PCR and normalized to
Gapdh. Three independent experiments were performed in triplicate
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by rotenone in mitochondria energized with succinate
suggests that reverse electron flow to complex I redox
centers is a major source of ROS production arising
from reducing equivalents entering the ETC. through
complex II in polarized mitochondria. In striking con-
trast, ROS production of liver mitochondria utilizing
complex I or II substrates were either unaffected or
slightly suppressed by these inhibitors.
The difference in effect of the inhibitors on liver
mitochondria might be suspected to be due to differen-
tial inhibition of enzymatic activity. However, when
assessing complex I (Fig. 3) or complex III (Fig. 4) en-
zymatic activity, each inhibitor had similar effects on
the two tissues. Therefore, the underlying mechanisms
of ROS production in brain and liver are likely distinct
and may reflect the different energy requirement of
each tissue. Mitochondria in highly energetically de-
manding neurons have evolved mechanisms by which
basal ROS production is low, however ETC. inhibitors
result in a drastic increase in ROS production which
may be important in many neurodegenerative condi-
tions, for instance the ability of rotenone to induce
parkinsonism [52]. The finding that inhibition within
the ETC in liver mitochondria did not cause significant
increases in ROS production suggests the possibility
that their redox centers are more sheltered from inter-
action with molecular oxygen. This may well represent
an evolutionary adaptation by liver mitochondria given
the relative abundance of toxins to which the liver can
be exposed that could potentially impair mitochondrial
function.
The effect of ETC. inhibitors on ROS production in
brain mitochondria oxidizing succinate can largely be
explained by their impact on Δψm. It is well known that
ROS production is highly dependent upon Δψm, espe-
cially by brain mitochondria oxidizing succinate [43, 53].
We observed similar effects of the inhibitors on brain
and liver mitochondria when respiration was supported
by either complex I or II substrates (Fig. 6). Loss of
Δψm likely impairs reverse electron flow to complex I,
thereby reducing ROS production. That similar effects
were not seen in liver mitochondria while the same de-
gree of depolarization was achieved suggests that reverse
electron flow does not play a major role in ROS produc-
tion in liver mitochondria using complex II substrates.
Importantly, the inhibition of ROS production in brain
mitochondria oxidizing succinate reflects inhibition of
FMN redox sites within complex I, as DPI was not
shown to have an effect on Δψm with succinate as a
substrate. This is in contrast to inhibition with rotenone,
which binds distally within complex I and inhibits the
reverse flow of electrons into complex I [54].
A caveat to the findings reported here is that brain
ROS production results were derived from both neurons
and glial cells, which could confound the interpretation
of the ROS signal. Indeed, neurons and glial cells differ
metabolically and may also differ in response to ETC. in-
hibitors. While the higher rates of oxidative metabol-
ism in neurons might lead to the assumption that they
will produce more ROS than glial cells, few studies
have directly compared the rates of basal ROS produc-
tion. Café et al. found no significant differences in
basal ROS production between glial and neuronal cells
although neurons were able to produce more ROS
under conditions of heightened oxidative stress [55].
While it is possible to study ROS production in primary
neuronal cultures as well as in glial cultures separately, in-
creasing evidence suggests that the neuron-glial interaction
is vital for the neuronal function [56, 57]. It has been shown
that astrocytes provide metabolic support to neurons as
well as providing structural support, modulating synaptic
activity and neurotransmitter homeostasis, and detoxifying
free radicals [58]. Furthermore, there is substantial variabil-
ity among different types of neurons with regard to func-
tion, metabolism, and susceptibility to oxidative stress [59].
Most importantly, utilizing glutamate and malate as sub-
strates, the vast majority of ROS production should derive
from neurons. Indeed, the activity of the malate-aspartate
shuttle has been demonstrated to be low if present at all in
astrocytes [60] with the aspartate-glutamate carrier likely
not present to a significant degree on glial cells [61].
Complex I inhibitors showed different degrees of in-
hibition of complex I supported respiration. Rotenone
inhibited respiration to a greater extent than DPI and
CMB (Fig. 5b, c), which is supported by our data show-
ing greater inhibition of complex I enzyme activity by
rotenone (Fig. 3b). DPI inhibited respiration in the pres-
ence of either complexes I or II substrates (Fig. 5), which
is consistent with the ability of DPI to react with flavo-
hydroquinones in both complexes I and II producing a
hydroxyl radical leading to subsequent flavoprotein in-
activation [62]. Indeed, we observed a similar reduction
in succinate supported respiration by DPI as has been
previously reported [63]. However, liver mitochondrial
complex II supported respiration showed resistance to in-
hibition by DPI (Fig. 5d, e), which may be due to decreased
inhibition of complex II but merits further investigation.
The putative complex I inhibitor CMB also strongly inhib-
ited succinate supported respiration in both brain and liver
mitochondria (Fig. 5d, e). This results from the nearly
complete ablation of complex III activity by CMB (4). CMB
likely inhibits more broadly than merely complex I redox
centers, potentially also having an inhibitory effect on the
electron carrying capacity of complex III. Significant differ-
ences were also observed between brain and liver mito-
chondria with regard to the percent inhibition of state 3
respiration supported by complex I substrates in response
to DPI and CMB (Fig. 5c), and state 3 respiration supported
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by complex II substrates in response to DPI and rotenone
(Fig. 5e). This differential response to the inhibitors is not
reflected in complex I enzymatic activity in response to
CMP, DPI, and rotenone, or the inhibitors’ effects on mito-
chondrial membrane potential. Future studies to describe
the mechanism of these compounds to differentially affect
mitochondrial respiration may focus on their effects on
supercomplex structure as well as on substrate availability.
State 2 and 3 respiratory activity comparing brain and
liver mitochondria in the absence of inhibitors exhibited
significant differences. Assaying either complex I or
complex II supported respiration, brain mitochondrial
oxygen consumption was approximately twice as high as
liver mitochondrial oxygen consumption. It has been
suggested that this may be secondary to increased com-
plex I and complex II enzyme activities in mitochondria
from brain relative to liver [64]. However, under our
assay conditions, there were no significant differences
between liver and brain mitochondria comparing the ac-
tivities of complexes I, II, or III (Figs. 3, and 4a, b). The
observation that both state 3 as well as state 2 respiration
are twice as high in brain compared to liver mitochondria
suggests that the difference is not due to variations in com-
plex V (ATP synthase) activity. Additionally, addition of the
complex V inhibitor oligomycin during state 3 respiration
resulted in oxygen consumption rates twice as high in brain
as in liver mitochondria (data not shown), further support-
ing the notion that upstream enzymatic activities were not
responsible for the difference in respiratory rate. While the
results herein assess membrane potential qualitatively
and may not be able to detect minor changes, the os-
tensibly similar state 2 membrane potential between
brain and liver mitochondria utilizing glutamate and
malate or succinate make changes in membrane poten-
tial an unlikely cause of the disparate respiratory rates
between the two tissues (Fig. 6).
Given the absence of differences in enzymatic activities
or membrane potential, differences in substrate trans-
port could account for differences in respiratory rates.
Variation in the activity of the malate-aspartate shuttle
between different tissues has been previously reported
[65]. Indeed, a three-fold increase in NADH transport
was observed in brain compared to liver mitochondria
(Fig. 7). To support the notion that increased complex I
respiration in brain mitochondria was due to increased
substrate transport we inhibited the malate-aspartate
shuttle with AOA. We showed that rates of respiration
could be normalized with AOA treatment and also
showed a greater degree of inhibition of brain mitochon-
drial respiration by AOA. The increased shuttle activity
in brain mitochondria may be required to provide aspar-
tate for N-acetylaspartate and myelin production [42].
Consistently, a homozygous mutation in the gene encod-
ing the glutamate-aspartate carrier (Slc25a12) has been
linked to psychomotor retardation, hypotonia, and hypo-
myelination of the central nervous system [66]. Slc25a12
knockout mice have also been shown to have growth re-
tardation, generalized tremor, motor deficits, decreased
survival, and impaired myelination [42]. Importantly,
variations in malate aspartate shuttle activity may differ
in response to mitochondrial calcium fluxes [44], with
transient calcium spikes during neuronal activity modu-
lating shuttle activity. Therefore, further in vivo studies
will be necessary to further characterize the interplay be-
tween substrate delivery and respiration under different
physiological conditions.
Differences in complex II supported respiration cannot
be attributed to differences in substrate transport. As
noted above, the gene expression of Slc25a10 was lower
in brain compared to liver mitochondria. There was also
no observed difference in complex II enzymatic activity
between brain and liver mitochondria (Fig. 4a). How-
ever, there was a 2.5 fold increase in complex II–III
coupled enzymatic activity (Fig. 8a), providing an ex-
planation for increased complex II driven respiration in
brain mitochondria. This is consistent with a previous
report indicating increased complex II–III coupled en-
zymatic activity in rat brain compared with liver mito-
chondria [36]. However, the mechanism underlying
differences in complex II–III coupled enzymatic activity
remains unclear. Complex II is known to physically associ-
ate with complex III [67], and the association of respiratory
complexes has been shown to regulate electron flux and re-
spiratory rates [68]. This interaction may differ between
brain and liver mitochondria, accounting for the difference
in coupled enzymatic activity. Furthermore, in compari-
son with liver mitochondria, brain mitochondria do
not maintain a storage pool of intermediates including
ubiquinone [38], which could drastically alter the
coupled complex II–III activity, the rate limiting step
which relies upon the reduction of ubiquinone.
Increased complex II supported respiration in brain
is consistent with previous reports; however, complex I
supported respiration has been shown to be slightly
higher in rat liver mitochondria compared with rat
brain mitochondria [48]. Thus, the increased complex
I supported respiration in brain and the mechanism of
increased NADH transport distinguishes mouse from
rat mitochondria. Whether this mechanism exists in
other species merits further investigation.
Conclusions
In this paper we have demonstrated important differ-
ences between mouse brain and liver mitochondria re-
garding their responses to ETC. inhibitors. Supported by
complex I substrates, brain mitochondria produce ele-
vated levels of ROS when either complex I or III is
inhibited, while liver mitochondrial ROS production is
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unchanged in the presence of the same inhibitors. Add-
itionally, the drastically elevated ROS levels in mouse
brain mitochondria utilizing succinate as a substrate is
inhibited to a greater extent by DPI and CMB than by
rotenone, myxothiazol, or antimycin A. This elevated
ROS is not present at all when assaying liver mitochon-
dria utilizing succinate and inhibitors result in a slight or
no reduction in ROS production. Many of these effects
can be explained in the context of the impact of these
inhibitors on complex I and III enzymatic activity, res-
piration, and membrane potential. We further demon-
strated that increased respiration in brain mitochondria can
in part be explained by increased substrate transport to
support complex I activity, and increased coupled complex
II–III activity while utilizing complex II substrates. These
results should be considered when assaying mouse mito-




C57BL/6 J (B6) mice were purchased from The Jackson La-
boratory (Bar Harbor, ME). Mice were maintained in the
Animal Care Services research animal facility at the Univer-
sity of Florida. All mice were bred and maintained in a spe-
cific pathogen-free vivarium and allowed free access to
food (Teklad Irradiated LM-485 Mouse/Rat Diet, Harlan
Teklad, Madison, WI) and drinking water. All procedures
involving animals were approved by the University of
Florida Institutional Animal Care and Use Committee and
were in compliance with “Principles of Laboratory Animal
Care” and the current laws of the United States of America.
Isolation of mitochondria from brain and liver
Brain mitochondria were isolated previously as described
[9, 69]. Briefly, Percoll dilutions were prepared in isola-
tion buffer I (IB I) (225 mM Mannitol, 75 mM Sucrose,
10 mM HEPES Potasium, 1 mM EDTA, 0.1 % fatty acid
free BSA, pH 7.4). All steps were performed at 4 °C. The
whole brain was excised, and homogenized in 12 %
Percoll, layered on top of a gradient of 24 % and 42 %
Percoll, and centrifuged at 27,000 × g for 10 min. The
mitochondrial fraction, located between the 24 % and
42 % layers, was removed with a syringe, diluted in IB
I, and centrifuged at 10,000 × g for 10 min. The super-
natant was discarded, and the pellet was re-suspended
in isolation buffer II (IB II) (225 mM Mannitol, 75 mM
Sucrose, 10 mM HEPES Potasium, 0.1 mM EDTA,
pH 7.4) and centrifuged at 10,000 × g for 10 min. The
supernatant was again discarded, and the pellet was re-
suspended in a total volume of 100 μL IB II. Protein con-
centrations for brain mitochondria as well as liver mito-
chondria preparations (described below) were determined
using the BCA protein assay (Pierce, Rockford, IL).
Liver mitochondria were isolated by differential centri-
fugation previously as described [10] and also using a
Percoll gradient. All steps were performed at 4 °C. For
isolation by differential centrifugation livers were re-
moved, washed in IB II, and then homogenized in IB I.
The homogenate was centrifuged at 1300 × g for 10 min.
The supernatant was saved and centrifuged at 10,000 × g
for 10 min. The supernatant was discarded and the pellet
was re-suspended in IB II and spun at 10,000 × g for
10 min. The resulting pellet was re-suspended in approxi-
mately 100 μL IB II. For isolation of liver mitochondria
using Percoll, livers were removed, washed in IB II, and
then homogenized in IB I. The homogenate was centri-
fuged at 1300 × g for 10 min, the supernatant saved, and
centrifuged at 10,000 × g for 10 min. Resulting pellets were
resuspended in 15 mL of 12 % Percoll, layered on top of a
gradient of 24 and 42 % Percoll, and centrifuged at
27,000 × g for 10 min. The mitochondrial fraction lo-
cated between the 24 and 42 % layers was removed
with a syringe, diluted in IB I, and centrifuged at
10,000 × g for 10 min. The supernatant was discarded,
and the pellet was re-suspended in IB II and centri-
fuged at 10,000 × g for 10 min. The resulting pellet was
re-suspended in 100 μL IB II.
Mitochondrial purity was determined by subjecting iso-
lated mitochondrial samples to Western blot analysis. Mito-
chondrial preparations were suspended in 100 μL lysis
buffer (50 mM Tris base, 137 mM NaCl, 10 % glycerol, 1 %
NP-40, 1 M NaF, 5 mg/ml leupeptin, 5 mg/ml aprotinin,
0.1 M Na3PO4, 0.33 M Phenylmethanesulfonyl fluoride).
Each protein sample (25 μg) was combined with an equal
volume of Laemmli Sample Buffer (Bio-Rad, Hercules,
CA), and boiled at 100 °C for 5 min. Samples were sepa-
rated on 12 % SDS-PAGE gels and transferred to nitrocellu-
lose, using standard procedures [70]. Western blotting was
performed with either an anti-cytochrome c oxidase
subunit IV (COX IV) antibody (Abcam, Cambridge,
MA) or an anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibody (Sigma, St. Louis, MO)
followed by horseradish peroxidase-conjugated Ig and
detection with enhanced chemiluminescence (Amer-
sham International, Amersham, UK). Chemilumines-
cence was detected with a FluorChem HD2 (Alpha
Innotech, Santa Clara, CA) and the images were col-
lected and analyzed using AlphaEaseFC software
(Alpha Innotech).
Measurements of mitochondria reactive oxygen species
production and mitochondrial transmembrane potential
Mitochondrial ROS production was assessed as previ-
ously described [9, 10]. All assays were performed with
constant stirring at 37 °C using 150 μg of mitochondrial
protein in 500 μL incubation media (IM) (125 mM KCL,
2 mM K2HPO4, 5 mM MgCl2, 10 mM HEPES, 10 μM
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EGTA, pH 7.2) in respiratory state 2 supplemented with
either 5 mM L-glutamate and 5 mM L-malate or 5 mM
succinate. ROS production was measured by continu-
ously recording the real-time oxidation of 2 μM Amplex
Red (Molecular Probes, Eugene, OR) to the fluorescent
molecule Resorufin, catalyzed by 1 U/mL horseradish
peroxidase. The use of Amplex Red primarily detects
ROS in the form of hydrogen peroxide [71]. Endogenous
dismutase activity was likely sufficient to metabolize all
of the superoxide produced in this system to hydrogen
peroxide as the addition of exogenous superoxide dis-
mutase did not increase the signal [43]. Fluorescence
was measured with an excitation wavelength of 560 nm
(slit 1.5 nm) and an emission wavelength of 590 nm
(slit 3 nm) using an RF-5301PC spectrofluorophot-
ometer (Shimadzu, Kyoto, Japan). Inhibitors of the
electron transport chain were added at the indicated
concentrations. To determine the optimal concentra-
tion of each inhibitor, titration curves using 0.1, 1, 5,
10, and 20 μM final concentrations of each inhibitor
were performed. ROS production was equal for the 5, 10,
and 20 μM doses of Complex I and Complex III inhibitors
in both brain and liver mitochondria (Additional file 1:
Table S1). For the studies included here we chose 10 μM of
each inhibitor (Fig. 2). Rates of ROS production were mea-
sured for at least 2 min for each treatment. All rates were
linear over the time interval measured. Vehicle alone
(DMSO at any concentration used) did not significantly
alter ROS production from either liver or brain mitochon-
dria utilizing glutamate and malate or succinate (Additional
file 1: Table S2). Slopes were converted into units of H2O2
(pmol / min / mg) as previously described [71]. As vehicle
did not alter the rate of basal ROS production, ROS pro-
duction after addition of ETC. inhibitor was compared to
the rate in incubation media alone.
Mitochondrial transmembrane potential (Δψm) was mea-
sured using the fluorescence quenching of cationic dye saf-
ranin O (2.5 μM). Mitochondria (150 μg) were added to
incubation media supplemented with either 5 mM L-glu-
tamate and 5 mM L-malate or 5 mM succinate followed by
the addition of 2.5 μM safranin O. Fluorescence was mea-
sured at excitation wavelength 495 nm (slit 3 nm) and
emission wavelength 586 nm (slit 10 nm).
Complex I (NADH:ubiquinone oxidoreductase) enzymatic
activity
Complex I activity was measured by monitoring the
oxidation of NADH at 340 nm as well as the reduction
of ubiquinone at 280 nm using a Spectramax E5 spec-
trofluorophotometer (Molecular Devices). The assay
medium contained potassium phosphate (25 mM,
pH 7.2 at 20 °C), 5 mM MgCl2, 2.5 mg/mL bovine
serum albumin (fraction V), and 2 mM KCN. Each re-
action was supplemented with 0.13 mM NADH, 65 μM
ubiquinone1, and 10 μg/mL antimycin A in a total vol-
ume of 200 μL. The reaction was initiated by the
addition of freeze fractured mitochondria (40 μg), and
the rates of oxidation of NADH and reduction of ubi-
quinone were simultaneously recorded. In parallel
wells, either 10 μM rotenone, 10 μM DPI, or 10 μM
CMB was added. The rate of change in absorbance was
measured for 3 minutes [72].
Complex II (succinate:ubiquinone oxidoreductace)
enzymatic activity
Complex II activity was measured by monitoring the re-
duction of 2,6-dichloroindophenolate (DCIP) at 600 nm
using a Spectramax E5 spectrofluorophotometer (Molecu-
lar Devices). The assay medium contained potassium
phosphate (25 mM, pH 7.2 at 20 °C), 5 mM MgCl2, and
20 mM sodium succinate. In parallel wells, malonate
(20 mM) was added. Mitochondria (8 μg/mL) were incu-
bated in the assay medium at 30 °C for 10 min. A baseline
was recorded for 1 min after the addition of 2 μg/ml
antimycin A, 2 μg/ml rotenone, 2 mM KCN, and 50 M
2,6-dichloroindophenolate in a total volume of 200 μL.
The reaction was initiated by the addition of 65 μM
ubiquinone1, and the rate of reduction of 2,6-dichlor-
oindophenolate was recorded for 3 min. The complex
II specific rate was determined by subtracting the mal-
onate insensitive activity from the total activity [72].
Complex II-Complex III coupled enzymatic activity
Complex II-III activity was determined by monitoring
the reduction of ferricytochrome c to ferrocytochrome
c at 550 nm using a Spectramax E5 spectrofluorophot-
ometer (Molecular Devices). Alamethicin was used to
permit cytochrome c binding within complex III while
maintain the integrity of the ETC. [73, 74]. The assay
medium contained potassium phosphate (25 mM,
pH 7.2 at 20 °C), 2.5 mM MgCl2, 2.5 mg/mL bovine
serum albumin, and 2 mM KCN. A baseline was re-
corded for 1 min at 550 nm after the addition of ala-
methicin (30 μg/mL), ferricytochrome c (15 μM), and
rotenone (2 μM) in a total volume of 200 μL. In paral-
lel wells, malonate (20 mM) was added. Reactions were
initiated with the addition of freshly isolated mitochondria
preincubated with succinate (20 mM) at 30 °C for 20 min
in potassium phosphate buffer. The rate of reduction was
recorded for 3 min. The coupled complex II–III specific
rate was determined by subtracting the malonate sensitive
activity from the total activity [75].
Complex III (cytochrome c reductase) enzymatic activity
Complex III activity was determined by monitoring the re-
duction of ferricytochrome c at 550 nm using a Spectramax
E5 spectrofluorophotometer (Molecular Devices). The
assay medium contained potassium phosphate (25 mM,
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pH 7.2 at 20 °C), 5 mM MgCl2, 2.5 mg/mL bovine serum
albumin (fraction V), and 2 mM KCN. The inclusion of
KCN precluded the re-oxidation of fererocytochrome c by
cytochrome c oxidase. Each reaction was supplemented
with 15 μM ferricytochrome c, 10 μM rotenone,
0.6 mM n-dodecyl-β-D-maltoside, and 35 μM ubiqui-
nol2 in a total volume of 200 μL. Ubiquinol2 was pre-
pared by dissolving 8 μg of ubiquinone in 1 mL of
ethanol; the solution was adjusted to pH 2 with 6 M
HCl. Ubiquinone was reduced using excess sodium bo-
rohydride. Ubiquinol2 was extracted into 2:1 (v/v)
diethylether:cyclohexane, evaporated under nitrogen
gas, dissolved in 1 mL ethanol, and acidified to pH 2
with 6 M HCl. Reactions were initiated by the addition
of mitochondria (20 μg) and the rate of reduction of
ferricytochrome c to ferrocytochrome c was recorded
for one minute. The rate was calculated based on the
first 10–15 s, which remained linear. In duplicate wells
either 10 μM antimycin A, 10 μM DPI, or 10 μM CMB
was added [72].
Oxygen consumption
Oxygen consumption was assessed using an Oxygraph-2 k
(Oroboros Instruments, Innsbruck, Austria). For each
measurement the chamber volume was 2 mL and a total of
0.4 mg of mitochondrial protein was added to MiR05 res-
piration medium. State 2 respiration was recorded after the
addition of mitochondria. State 3 respiration was induced
by the addition of ADP (0.5 mM final concentration). After
maximum activated respiration was reached, the indicated
inhibitor was added. All rates were recorded for at least
three minutes.
Mitochondrial respiration was also studied after the
addition of aminooxyacetate (AOA), which inhibits the
malate-aspartate shuttle by inhibiting aspartate amino
transferases [76]. State 2 respiration was recorded after
the addition of complex I substrates glutamate and mal-
ate. State 3 respiration was induced with ADP at 1 mM
final concentration to generate a sustained activated re-
spiratory state. AOA was introduced stepwise into the
reaction chamber in additive 1 mM doses, 3 min apart,
until respiration was inhibited to levels equal to or less
than state 2 respiration.
Measurement of malate-aspartate shuttle activity
The capacity to transport NADH by the malate-aspartate
shuttle was assessed in both isolated brain and liver mito-
chondria by following the decrease in NADH fluorescence
at 340 nm using an RF-5301PC spectrofluorophotometer
(Shimadzu) as previously described [77].
RT-PCR
RNA was purified from brain and liver using TRIzol
Reagent (Life Technologies, Rockville, MD). cDNA was
generated using the SUPERSCRIPT Choice System
(Life Technologies, Carlsbad, CA). Primer sets, specific
for Slc25a10, mt-Cyb, mt-Co2, and Actb (beta-Actin)
[78] were purchased from Qiagen (Valencia, CA). Tests
were run on a LightCycler 480 (Roche, Indianapolis,
IN), using SYBR Green Supermix (BioRad, Hercules,
CA) for detection as per manufacturer’s protocol in a
total volume of 50 μL. All PCR consisted of an initial
10 min denaturation step at 95 °C, followed by 45 two-step
cycles of (95 °C for 10 s, 60 °C for 30 s). Detection was per-
formed during each 60 °C extension step. After the 45th
cycle a melt-curve was run to assess specificity. To further
determine specific amplification the reaction products were
run on 4 % agarose gels as previously described [79, 80].
Chemicals
All chemicals were obtained from Sigma-Aldrich Co. unless
otherwise noted. Stock solutions of rotenone and antimycin
A were prepared in ethanol. Other ETC. inhibitor stock so-
lutions were prepared in dimethyl sulfoxide (DMSO). All
working dilutions of ETC. inhibitors were prepared in incu-
bation media.
Data analysis
Statistical analysis was performed using Prism 5 (Graph-
pad Software, La Jolla, CA). Data are represented as
means ± SEM, with means considered to be significantly
different at p < 0.05.
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